HOME Meetings and Progress on COS

HOME XII (London, UK)

The HOME XII meeting will take place on 3rd and 4th June 2026.  The aim of the meeting is to revisit the HOME COS after 7 years of implementation.

HOME XI (Berlin, Germany)

The HOME XI meeting took place on 10th October ahead of the 2023 EADV Conference.  We continued our drive for implementation of the clinical trials core outcome set, focussing on the next steps of the implementation projects that started in the HOME X meeting.

HOME X (Montreal, Canada)

This meeting took place on 15th and 16th October 2022 ahead of the ISAD meeting.  Two sessions were held:
Day 1 - Implementation of the Core Outcome Set
Day 2 - Clinical practice set - clinical signs

Joint COUSIN/HOME meeting

The CS-COUSIN meeting took place virtually from 23rd to 28th September 2021 and was an opportunity to bring together all of the different core outcome set groups in dermatology.  

HOME VIII 

Discussions will focus on identifing instrument(s) that are suitable for use in clinical practice for measuring itch and disease control.

HOME VII (Tokyo, Japan)

Discussions focused on reaching consensus for the Quality-of-life and Long-term control domains.

HOME VI (Utrecht, The Netherlands)

Discussions concerned identifying valid and feasible outcome measurement instruments for atopic eczema in routine clinical practice.

HOME V (Nantes, France)

Consensus was reached to recommend repeated measures of the signs, symptoms (including intensity of itch) and QoL for measuring long-term control in eczema trials. 

Instruments for measuring quality of life in children were assessed but no consensus was reached on recommending a core outcome instrument.

HOME IV (Malmö, Sweden)

Consensus was reached to recommend POEM as the core outcome instrument for measuring patient-reported symptoms in eczema trials. 

Instruments for measuring quality of life (QoL) in adults were assessed but no consensus was reached on recommending a core outcome instrument.

HOME III (San Diego, USA)

Consensus was reached to reccomend EASI as the core outcome instrument for measuring clinican reported signs of eczema trials.

HOME II (Amsterdam, the Netherlands)

Agreed the domains for the core outcome set as; clinician reported signs, patient reported symptoms, quality of life and long term control.

HOME I (Munich, Germany)

Determined there was sufficient interest to set up a HOME initiative to develop a COS.

An e-Delphi identified a preliminary core set of outcome domains for clinical trials and clinical record keeping.